The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice
Abstract
Objective: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults. Background: The American Headache Society previously published a Consensus Statement on the use of newly introduced treatments for adults with migraine. This update, which is based on the expanded evidence base and emerging expert consensus concerning postapproval usage, provides practical recommendations in the absence of a formal guideline. Methods: This update involved four steps: (1) review of data about the efficacy, safety, and clinical use of migraine treatments introduced since the previous Statement was published; (2) incorporation of these data into a proposed update; (3) review and commentary by the Board of Directors of the American Headache Society and patients and advocates associated with the American Migraine Foundation; (4) consideration of these collective insights and integration into an updated Consensus Statement. Results: Since the last Consensus Statement, no evidence has emerged to alter the established principles of either acute or preventive treatment. Newly introduced acute treatments include two small‐molecule calcitonin gene‐related peptide (CGRP) receptor antagonists (ubrogepant, rimegepant); a serotonin (5‐HT 1F ) agonist (lasmiditan); a nonsteroidal anti‐inflammatory drug (celecoxib oral solution); and a neuromodulatory device (remote electrical neuromodulation). New preventive treatments include an intravenous anti‐CGRP ligand monoclonal antibody (eptinezumab). Several modalities, including neuromodulation (electrical trigeminal nerve stimulation, noninvasive vagus nerve stimulation, single‐pulse transcranial magnetic stimulation) and biobehavioral therapy (cognitive behavioral therapy, biofeedback, relaxation therapies, mindfulness‐based therapies, acceptance and commitment therapy) may be appropriate for either acute and/or preventive treatment; a neuromodulation device may be appropriate for acute migraine treatment only (remote electrical neuromodulation). Conclusions: The integration of new treatments into clinical practice should be informed by the potential for benefit relative to established therapies, as well as by the characteristics and preferences of individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adherence to Long‐Term Therapies: Evidence for Action
Burkhart, P. V., & Sabaté, E. (2003) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2003.tb00001.x · Cited by 2,526
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Feigin, V. L., Abajobir, A. A., Abate, K. H., Abd-Allah, F., Abdulle, A. M., Abera, S. F., Abyu, G. Y., Ahmed, M. B., Aichour, A. N., Aichour, I., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30299-5 · Cited by 2,275
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
Stewart, W. F. (1992) · JAMA · doi:10.1001/jama.267.1.64 · Cited by 1,583
Quantifying the burden of disease: the technical basis for disability-adjusted life years.
Murray, C. J. L. (1994) · Europe PMC (PubMed Central) · Cited by 1,581
Silberstein, S. D. (2000) · Neurology · doi:10.1212/wnl.55.6.754 · Cited by 1,360
Stewart, W. F., Lipton, R. B., Dowson, A. J., & Sawyer, J. (2001) · Neurology · doi:10.1212/wnl.56.suppl_1.s20 · Cited by 1,210
Aurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., Diener, H., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364676 · Cited by 1,047
An association between migraine and cutaneous allodynia
Burstein, R., Yarnitsky, D., Goor-Aryeh, I., Ransil, B. J., & Bajwa, Z. H. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200005)47:5<614::aid-ana9>3.0.co;2-n · Cited by 1,016
Diener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., Silberstein, S., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364677 · Cited by 960
A Controlled Trial of Erenumab for Episodic Migraine
Goadsby, P. J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J. H., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1705848 · Cited by 928
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Bigal, M. E., Serrano, D., Buse, D., Scher, A., Stewart, W. F., & Lipton, R. B. (2008) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2008.01217.x · Cited by 845
Fremanezumab for the Preventive Treatment of Chronic Migraine
Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709038 · Cited by 792
Tepper, S., Ashina, M., Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D., & Lenz, R. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30083-2 · Cited by 722
Cutaneous allodynia in the migraine population
Lipton, R. B., Bigal, M. E., Ashina, S., Burstein, R., Silberstein, S., Reed, M. L., Serrano, D., Stewart, W. F., & American Migraine Prevalence Prevention Advisory Group (2008) · Annals of Neurology · doi:10.1002/ana.21211 · Cited by 598
Marmura, M. J., Silberstein, S. D., & Schwedt, T. J. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12499 · Cited by 568
American Headache Society (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13456 · Cited by 567
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
Dodick, D. W., Ashina, M., Brandes, J. L., Kudrow, D., Lanteri-Minet, M., Osipova, V., Palmer, K., Picard, H., Mikol, D. D., & Lenz, R. A. (2018) · Cephalalgia · doi:10.1177/0333102418759786 · Cited by 566
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Detke, H. C., Goadsby, P. J., Wang, S., Friedman, D. I., Selzler, K. J., & Aurora, S. K. (2018) · Neurology · doi:10.1212/wnl.0000000000006640 · Cited by 563
Dodick, D. W., Silberstein, S. D., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2018) · JAMA · doi:10.1001/jama.2018.4853 · Cited by 562
Stauffer, V. L., Dodick, D. W., Zhang, Q., Carter, J. N., Ailani, J., & Conley, R. R. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1212 · Cited by 559
Self-citationAdherence to oral migraine-preventive medications among patients with chronic migraine
Hepp, Z., Dodick, D. W., Varon, S. F., Gillard, P., Hansen, R. N., & Devine, E. B. (2015) · Cephalalgia · doi:10.1177/0333102414547138 · Cited by 433
Croop, R., Goadsby, P. J., Stock, D. A., Conway, C. M., Forshaw, M., Stock, E. G., Coric, V., & Lipton, R. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31606-x · Cited by 403
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
Lipton, R. B., Croop, R., Stock, E. G., Stock, D. A., Morris, B. A., Frost, M., Dubowchik, G. M., Conway, C. M., Coric, V., & Goadsby, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811090 · Cited by 398
Tassorelli, C., Diener, H.-C., Dodick, D. W., Silberstein, S. D., Lipton, R. B., Ashina, M., Becker, W. J., Ferrari, M. D., Goadsby, P. J., Pozo-Rosich, P., et al. (2018) · Cephalalgia · doi:10.1177/0333102418758283 · Cited by 388
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Lipton, R. B., Goadsby, P. J., Smith, J., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B., & Cady, R. (2020) · Neurology · doi:10.1212/wnl.0000000000009169 · Cited by 388
Blumenfeld, A. M., Bloudek, L. M., Becker, W. J., Buse, D. C., Varon, S. F., Maglinte, G. A., Wilcox, T. K., Kawata, A. K., & Lipton, R. B. (2013) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12055 · Cited by 380
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Ashina, M., Saper, J., Cady, R., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B., & Smith, J. (2020) · Cephalalgia · doi:10.1177/0333102420905132 · Cited by 380
Lipton, R. B., Stewart, W. F., Stone, A. M., Láinez, M. J. A., & Sawyer, J. P. C. (2000) · JAMA · doi:10.1001/jama.284.20.2599 · Cited by 363
Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial
Schoenen, J., Vandersmissen, B., Jeangette, S., Herroelen, L., Vandenheede, M., Gérard, P., & Magis, D. (2013) · Neurology · doi:10.1212/wnl.0b013e3182825055 · Cited by 360
Croop, R., Lipton, R. B., Kudrow, D., Stock, D. A., Kamen, L., Conway, C. M., Stock, E. G., Coric, V., & Goadsby, P. J. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32544-7 · Cited by 360
Dodick, D., Lipton, R. B., Martin, V., Papademetriou, V., Rosamond, W., MaassenVanDenBrink, A., Loutfi, H., Welch, K. M., Goadsby, P. J., Hahn, S., et al. (2004) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2004.04078.x · Cited by 351
Ubrogepant for the Treatment of Migraine
Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Finnegan, M., Trugman, J. M., & Szegedi, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813049 · Cited by 349
Self-citationIneffective acute treatment of episodic migraine is associated with new-onset chronic migraine
Lipton, R. B., Fanning, K. M., Serrano, D., Reed, M. L., Cady, R., & Buse, D. C. (2015) · Neurology · doi:10.1212/wnl.0000000000001256 · Cited by 315
Buse, D. C., Reed, M. L., Fanning, K. M., Bostic, R., Dodick, D. W., Schwedt, T. J., Munjal, S., Singh, P., & Lipton, R. B. (2020) · The Journal of Headache and Pain · doi:10.1186/s10194-020-1084-y · Cited by 307
Munakata, J., Hazard, E., Serrano, D., Klingman, D., Rupnow, M. F. T., Tierce, J., Reed, M., & Lipton, R. B. (2009) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2009.01369.x · Cited by 299
Powers, S. W., Kashikar-Zuck, S. M., Allen, J. R., LeCates, S. L., Slater, S. K., Zafar, M., Kabbouche, M. A., O’Brien, H. L., Shenk, C. E., Rausch, J. R., et al. (2013) · JAMA · doi:10.1001/jama.2013.282533 · Cited by 287
Lipton, R. B., Dodick, D. W., Ailani, J., Lu, K., Finnegan, M., Szegedi, A., & Trugman, J. M. (2019) · JAMA · doi:10.1001/jama.2019.16711 · Cited by 279
Self-citationCanadian Headache Society guideline for migraine prophylaxis.
Pringsheim, T. M., Davenport, W. J., Mackie, G. F., Worthington, I., Aubé, M., Christie, S. N., Gladstone, J. P., & Becker, W. J. (2012) · PubMed · Cited by 278
Silberstein, S. D. (2015) · Continuum · doi:10.1212/con.0000000000000199 · Cited by 278
Cutaneous allodynia as a predictor of migraine chronification
Louter, M. A., Bosker, J. E., van Oosterhout, W. P. J., van Zwet, E. W., Zitman, F. G., Ferrari, M. D., & Terwindt, G. M. (2013) · Brain · doi:10.1093/brain/awt251 · Cited by 278
Goadsby, P. J., Wietecha, L. A., Dennehy, E. B., Kuca, B., Case, M. G., Aurora, S. K., & Gaul, C. (2019) · Brain · doi:10.1093/brain/awz134 · Cited by 274
Biofeedback Treatment for Headache Disorders: A Comprehensive Efficacy Review
Nestoriuc, Y., Martin, A., Rief, W., & Andrasik, F. (2008) · Applied Psychophysiology and Biofeedback · doi:10.1007/s10484-008-9060-3 · Cited by 273
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
Kuca, B., Silberstein, S. D., Wietecha, L., Berg, P. H., Dozier, G., Lipton, R. B., on behalf of the COL MIG-301 Study Group, COL MIG-301 Study Group, Adams, M., Alftine, C., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006641 · Cited by 270
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Ho, T. W., Connor, K. M., Zhang, Y., Pearlman, E., Koppenhaver, J., Fan, X., Lines, C., Edvinsson, L., Goadsby, P. J., & Michelson, D. (2014) · Neurology · doi:10.1212/wnl.0000000000000771 · Cited by 262
Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study
Tassorelli, C., Grazzi, L., de Tommaso, M., Pierangeli, G., Martelletti, P., Rainero, I., Dorlas, S., Geppetti, P., Ambrosini, A., Sarchielli, P., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005857 · Cited by 254 · cited 3×
“Neuromodulatory devices can also be considered (electrical trigeminal nerve stimulation [eTNS] 53,54 ; noninvasive vagus nerve stimulation [nVNS] 44 ; remote electrical neuromodulation [REN] 45,46 ; or single-pulse transcranial magnetic stimulation [sTMS] 42 ).”
BackgroundMethodDiener, H.-C., Tassorelli, C., Dodick, D. W., Silberstein, S. D., Lipton, R. B., Ashina, M., Becker, W. J., Ferrari, M. D., Goadsby, P. J., Pozo-Rosich, P., et al. (2019) · Cephalalgia · doi:10.1177/0333102419828967 · Cited by 243
Buse, D., Manack, A., Serrano, D., Reed, M., Varon, S., Turkel, C., & Lipton, R. (2012) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2011.02046.x · Cited by 239
Goadsby, P. J., Dodick, D. W., Ailani, J., Trugman, J. M., Finnegan, M., Lu, K., & Szegedi, A. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30234-9 · Cited by 230
Self-citationSerrano, D., Lipton, R. B., Scher, A. I., Reed, M. L., Stewart, W. F., Adams, A. M., & Buse, D. C. (2017) · The Journal of Headache and Pain · doi:10.1186/s10194-017-0787-1 · Cited by 227
Holroyd, K. A., Cottrell, C. K., O'Donnell, F. J., Cordingley, G. E., Drew, J. B., Carlson, B. W., & Himawan, L. (2010) · BMJ · doi:10.1136/bmj.c4871 · Cited by 222
Diener, H.-C., Tassorelli, C., Dodick, D. W., Silberstein, S. D., Lipton, R. B., Ashina, M., Becker, W. J., Ferrari, M. D., Goadsby, P. J., Pozo-Rosich, P., et al. (2020) · Cephalalgia · doi:10.1177/0333102420941839 · Cited by 222
Goadsby, P., Zanchin, G., Geraud, G., de Klippel, N., Diaz-Insa, S., Gobel, H., Cunha, L., Ivanoff, N., Falques, M., & Fortea, J. (2008) · Cephalalgia · doi:10.1111/j.1468-2982.2008.01546.x · Cited by 221
Buse, D. C., Scher, A. I., Dodick, D. W., Reed, M. L., Fanning, K. M., Manack Adams, A., & Lipton, R. B. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.02.013 · Cited by 197
Wells, R. E., O’Connell, N., Pierce, C. R., Estave, P., Penzien, D. B., Loder, E., Zeidan, F., & Houle, T. T. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.7090 · Cited by 183
Chou, D. E., Shnayderman Yugrakh, M., Winegarner, D., Rowe, V., Kuruvilla, D., & Schoenen, J. (2019) · Cephalalgia · doi:10.1177/0333102418811573 · Cited by 176
Stovner, L. J., Linde, M., Gravdahl, G. B., Tronvik, E., Aamodt, A. H., Sand, T., & Hagen, K. (2014) · Cephalalgia · doi:10.1177/0333102413515348 · Cited by 174
Skljarevski, V., Oakes, T. M., Zhang, Q., Ferguson, M. B., Martinez, J., Camporeale, A., Johnson, K. W., Shan, Q., Carter, J., Schacht, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3859 · Cited by 172
Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study
Goadsby, P. J., Silberstein, S. D., Yeung, P. P., Cohen, J. M., Ning, X., Yang, R., & Dodick, D. W. (2020) · Neurology · doi:10.1212/wnl.0000000000010600 · Cited by 172
Diener, H.-C., Agosti, R., Allais, G., Bergmans, P., Bussone, G., Davies, B., Ertas, M., Lanteri-Minet, M., Reuter, U., Del Río, M. S., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70272-7 · Cited by 163
Starling, A. J., Tepper, S. J., Marmura, M. J., Shamim, E. A., Robbins, M. S., Hindiyeh, N., Charles, A. C., Goadsby, P. J., Lipton, R. B., Silberstein, S. D., et al. (2018) · Cephalalgia · doi:10.1177/0333102418762525 · Cited by 162
Self-citationValidating Migraine‐Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine
Bagley, C. L., Rendas‐Baum, R., Maglinte, G. A., Yang, M., Varon, S. F., Lee, J., & Kosinski, M. (2012) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2011.01997.x · Cited by 160
Yarnitsky, D., Dodick, D. W., Grosberg, B. M., Burstein, R., Ironi, A., Harris, D., Lin, T., & Silberstein, S. D. (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13551 · Cited by 160
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
Dodick, D. W., Lipton, R. B., Silberstein, S. D., Goadsby, P. J., Biondi, D. M., Hirman, J., Cady, R. K., & Smith, J. (2019) · Cephalalgia · doi:10.1177/0333102419858355 · Cited by 155
Coeytaux, R. R., Kaufman, J. S., Chao, R. A., Mann, J. D., & DeVellis, R. F. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.05.010 · Cited by 154
Non-Pharmacological Approaches for Migraine
Puledda, F., & Shields, K. G. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0623-6 · Cited by 143
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
Camporeale, A., Kudrow, D., Sides, R., Wang, S., Dycke, A. V., Selzler, K. J., & Stauffer, V. L. (2018) · BMC Neurology · doi:10.1186/s12883-018-1193-2 · Cited by 140
Premonitory symptoms in migraine: A cross-sectional study in 2714 persons
Laurell, K., Artto, V., Bendtsen, L., Hagen, K., Häggström, J., Linde, M., Söderström, L., Tronvik, E., Wessman, M., Zwart, J., et al. (2015) · Cephalalgia · doi:10.1177/0333102415620251 · Cited by 138
Serrano, D., Manack, A. N., Reed, M. L., Buse, D. C., Varon, S. F., & Lipton, R. B. (2013) · Value in Health · doi:10.1016/j.jval.2012.08.2212 · Cited by 130
(1990) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1990.tb00847.x · Cited by 126
Validity and Reliability of the Migraine-Treatment Optimization Questionnaire
Lipton, R. B., Kolodner, K., Bigal, M., Valade, D., Lainez, M., Pascual, J., Gendolla, A., Bussone, G., Islam, N., Albert, K. S., et al. (2009) · Cephalalgia · doi:10.1111/j.1468-2982.2008.01786.x · Cited by 118
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
Berman, G., Croop, R. S., Kudrow, D., Halverson, P. C., Lovegren, M., Thiry, A., Conway, C. M., Coric, V., & Lipton, R. B. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13930 · Cited by 114
SEEDS for success: Lifestyle management in migraine
Robblee, J. V., & Starling, A. J. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.19009 · Cited by 112
Harris, P., Loveman, E., Clegg, A. J., Easton, S., & Berry, N. (2015) · British Journal of Pain · doi:10.1177/2049463715578291 · Cited by 111
Tepper, S. J., Ashina, M., Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S. D., Winner, P. K., Zhang, F., Cheng, S., & Mikol, D. D. (2020) · Cephalalgia · doi:10.1177/0333102420912726 · Cited by 111
Seng, E. K., Singer, A. B., Metts, C., Grinberg, A. S., Patel, Z. S., Marzouk, M., Rosenberg, L., Day, M., Minen, M. T., Lipton, R. B., et al. (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13657 · Cited by 103
Ailani, J., Lipton, R. B., Hutchinson, S. L., Knievel, K. L., Lu, K., Butler, M. J., Yu, S. Y., Finnegan, M., Severt, L., & Trugman, J. M. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13682 · Cited by 102
Self-citationVascular safety of erenumab for migraine prevention
Kudrow, D., Pascual, J., Winner, P. K., Dodick, D. W., Tepper, S. J., Reuter, U., Hong, F., Klatt, J., Zhang, F., Cheng, S., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008743 · Cited by 97
Silberstein, S. D., Dodick, D. W., Freitag, F. G., Pearlman, S. H., Hahn, S. R., Scher, I., & Lipton, R. B. (2007) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2007.00760.x · Cited by 94
Biofeedback in headache: An overview of approaches and evidence
Andrasik, F. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77.s3.13 · Cited by 90
Mannix, S., Skalicky, A. M., Buse, D. C., Desai, P., Sapra, S. J., Ortmeier, B. G., Widnell, K. L., & Hareendran, A. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0542-3 · Cited by 89
Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
Kanaan, S., Hettie, G., Loder, E., & Burch, R. C. (2020) · Cephalalgia · doi:10.1177/0333102420946725 · Cited by 88
Self-citationThe Impact of Topiramate on Health‐Related Quality of Life Indicators in Chronic Migraine
Dodick, D. W., Silberstein, S. D., Saper, J. R., Freitag, F. G., Cady, R. K., Rapoport, A. M., Mathew, N. T., Hulihan, J. F., Crivera, C., Rupnow, M. F. T., et al. (2007) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2007.00950.x · Cited by 83
Revised French guidelines for the diagnosis and management of migraine in adults and children
Lantéri‐Minet, M., Valade, D., Geraud, G. E. A., Lucas, C., & Donnet, A. (2014) · The Journal of Headache and Pain · doi:10.1186/1129-2377-15-2 · Cited by 82
Holroyd, K. A., & Penzien, D. B. (1994) · Behavioral Medicine · doi:10.1080/08964289.1994.9934617 · Cited by 78
Smelt, A. F., Louter, M. A., Kies, D. A., Blom, J. W., Terwindt, G. M., van der Heijden, G. J. M. G., Gucht, V. D., Ferrari, M. D., & Assendelft, W. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098933 · Cited by 78
Dodick, D., & Silberstein, S. D. (2007) · Practical Neurology · doi:10.1136/jnnp.2007.134023 · Cited by 77
Headaches in over 12s: diagnosis and management
Crosland, P. (2015) · Deakin Research Online (Deakin University) · Cited by 76
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
Raffaelli, B., Mussetto, V., Israel, H., Neeb, L., & Reuter, U. (2019) · The Journal of Headache and Pain · doi:10.1186/s10194-019-1018-8 · Cited by 72
Differential medication overuse risk of novel anti-migraine therapeutics
Saengjaroentham, C., Strother, L. C., Dripps, I. J., Jabir, M. R. S., Pradhan, A. A. A., Goadsby, P. J., & Holland, P. R. (2020) · Brain · doi:10.1093/brain/awaa211 · Cited by 71
Remote electrical neuromodulation for acute treatment of migraine in adolescents
Hershey, A. D., Lin, T., Gruper, Y., Harris, D., Ironi, A., Berk, T., Szperka, C. L., & Berenson, F. R. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14042 · Cited by 70
Cady, R. K., McAllister, P. J., Spierings, E. L. H., Messina, J. C., Carothers, J. L., Djupesland, P. G., & Mahmoud, R. A. (2014) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12472 · Cited by 68
National Trends in Direct Health Care Expenditures Among US Adults With Migraine: 2004 to 2013
Raval, A. D., & Shah, A. (2016) · Journal of Pain · doi:10.1016/j.jpain.2016.10.005 · Cited by 68
Matsuzawa, Y. K., Lee, Y. S. C., Fraser, F., Langenbahn, D. M., Shallcross, A. J., Powers, S. W., Lipton, R. B., Simon, N. M., & Minen, M. T. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13429 · Cited by 68
Ashina, M., Kudrow, D., Reuter, U., Doležil, D., Silberstein, S. D., Tepper, S. J., Xue, F., Picard, H., Zhang, F., Wang, A., et al. (2019) · Cephalalgia · doi:10.1177/0333102419888222 · Cited by 68
Dodick, D. W., Lipton, R. B., Ailani, J., Singh, R. B. H., Shewale, A. R., Zhao, S., Trugman, J. M., Yu, S. Y., & Viswanathan, H. N. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13766 · Cited by 68
Self-citationChou, D. E., Gross, G. J., Casadei, C. H., & Yugrakh, M. S. (2017) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.12623 · Cited by 67
Patients’ preferences for headache acute and preventive treatment
on behalf of the Hellenic Headache Society, Mitsikostas, D. D., Belesioti, I., Arvaniti, C., Mitropoulou, E., Deligianni, C. I., Kasioti, E., Constantinidis, T. S., Dermitzakis, M., & Vikelis, M. (2017) · The Journal of Headache and Pain · doi:10.1186/s10194-017-0813-3 · Cited by 67
The role of headache-related disability in migraine management
Lipton, R. B., & Silberstein, S. D. (2001) · Neurology · doi:10.1212/wnl.56.suppl_1.s35 · Cited by 63
Dowson, A. J., Tepper, S. J., Baos, V., Baudet, F., D’Amico, D., & Kilminster, S. G. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004079 · Cited by 63
Minen, M. T., Adhikari, S., Padikkala, J., Tasneem, S., Bagheri, A., Goldberg, E., Powers, S. W., & Lipton, R. B. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14010 · Cited by 62
Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Open‐Label Study
Irwin, S. L., Qubty, W. F., Allen, I. E., Patniyot, I. R., Goadsby, P. J., & Gelfand, A. A. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13284 · Cited by 57
Tepper, S. J., Cady, R. K., Silberstein, S. D., Messina, J. C., Mahmoud, R. A., Djupesland, P. G., Shin, P., & Siffert, J. O. (2015) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12583 · Cited by 55
Grazzi, L., Egeo, G., Liebler, E. J., Padovan, A. M., & Barbanti, P. (2017) · Neurological Sciences · doi:10.1007/s10072-017-2942-5 · Cited by 54
Acute Migraine Treatment: Patterns of Use and Satisfaction in a Clinical Population
Malik, S. N., Hopkins, M. M., Young, W. B., & Silberstein, S. D. (2006) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00437.x · Cited by 53
Rapoport, A. M., Bonner, J. H., Lin, T., Harris, D., Gruper, Y., Ironi, A., & Cowan, R. P. (2019) · The Journal of Headache and Pain · doi:10.1186/s10194-019-1033-9 · Cited by 47
Physician and patient preferences for dosing options in migraine prevention
Cowan, R. P., Cohen, J. M., Rosenman, E. S., & Iyer, R. G. (2019) · The Journal of Headache and Pain · doi:10.1186/s10194-019-0998-8 · Cited by 46
Vasiliou, V. S., Karademas, E. C., Christou, Y., Papacostas, S., & Karekla, M. (2021) · The Journal of Pain · doi:10.1016/j.jpain.2020.06.006 · Cited by 45
Kawata, A. K., Hsieh, R., Bender, R. H., Shaffer, S., Revicki, D. A., Bayliss, M. S., Buse, D. C., Desai, P., Sapra, S. J., Ortmeier, B. G., et al. (2017) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13162 · Cited by 44
Stauffer, V. L., Wang, S., Voulgaropoulos, M., Skljarevski, V., Kovacik, A. J., & Aurora, S. K. (2019) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13508 · Cited by 44
Acute Migraine Treatment Outcome Measures: A Clinician's View
Sheftell, F., & Fox, A. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.0200s2014.x · Cited by 42
Revicki, D. A., Kimel, M., Beusterien, K., Kwong, J. W., Varner, J., Ames, M. H., Mahajan, S., & Cady, R. K. (2006) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00289.x · Cited by 41
Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis
Al-Asa'd, Y., & Asha, M. Z. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.105900 · Cited by 40
Cousins, S., Ridsdale, L., Goldstein, L. H., Noble, A. J., Moorey, S., & Seed, P. T. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7916-z · Cited by 39
Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache
Rau, J. C., Navratilova, E., Oyarzo, J. N., Johnson, K. W., Aurora, S. K., Schwedt, T. J., Dodick, D. W., & Porreca, F. (2020) · Cephalalgia · doi:10.1177/0333102420920006 · Cited by 39
Drug safety in acute migraine treatment
Tajti, J., Majláth, Z., Szok, D., Csáti, A., & Vécsei, L. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1026325 · Cited by 38
Grazzi, L., Bernstein, C., Raggi, A., Sansone, E., Grignani, E., Searl, M., & Rizzoli, P. (2019) · Neurological Sciences · doi:10.1007/s10072-019-03802-w · Cited by 35
Marcus, S. C., Shewale, A. R., Silberstein, S. D., Lipton, R. B., Young, W. B., Viswanathan, H. N., & Doshi, J. A. (2020) · Cephalalgia · doi:10.1177/0333102420915167 · Cited by 35
Katsarava, Z., Holle, D., & Diener, H. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0019-4 · Cited by 33
Cady, R. K., Munjal, S., Cady, R. J., Manley, H. R., & Brand‐Schieber, E. (2017) · The Journal of Headache and Pain · doi:10.1186/s10194-016-0717-7 · Cited by 33
Effects of Switching Acute Treatment on Disability in Migraine Patients Using Triptans
Serrano, D., Buse, D. C., Kori, S. H., Papapetropoulos, S., Cunanan, C. M., Manack, A. N., Reed, M. L., & Lipton, R. B. (2013) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12164 · Cited by 26
Munjal, S., Brand‐Schieber, E., Allenby, K. S., et al. (2017) · The Journal of Headache and Pain · doi:10.1186/s10194-017-0740-3 · Cited by 25
Biofeedback Treatment App for Pediatric Migraine: Development and Usability Study
Stubberud, A., Tronvik, E., Olsen, A., Gravdahl, G. B., & Linde, M. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13772 · Cited by 25
Marmura, M. J., Lin, T., Harris, D., Ironi, A., & Rosen, N. L. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00226 · Cited by 25
Silberstein, S. D., Cady, R. K., Sheftell, F. D., Almas, M., Parsons, B., & Albert, K. S. (2006) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00633.x · Cited by 24
Buse, D. C., Serrano, D., Reed, M. L., Kori, S. H., Cunanan, C. M., Adams, A. M., & Lipton, R. B. (2015) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12556 · Cited by 23
Stanak, M., Wolf, S., Jagoš, H., & Zebenholzer, K. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116725 · Cited by 23
Quality improvement in neurology: Headache Quality Measurement Set
Robbins, M. S., Victorio, M. C., Bailey, M., Cook, C. L., Garza, I., Huff, J. S., Ready, D. M., Schuster, N. M., Seidenwurm, D. J., Seng, E. K., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010634 · Cited by 23
Self-citationRemote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine
Rapoport, A. M., Lin, T., & Tepper, S. J. (2019) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13669 · Cited by 21
Sansone, E., Grazzi, L., Raggi, A., Leonardi, M., & D’Amico, D. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04662-5 · Cited by 10
Quality Improvement in Neurology: Headache Quality Measurement Set
Robbins, M. S., Victorio, M. C., Bailey, M., Cook, C. L., Garza, I., Huff, J. S., Ready, D. M., Schuster, N. M., Seidenwurm, D. J., Seng, E. K., et al. (2020) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13988 · Cited by 9
Self-citation
Cited by
Kynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders
Fila, M., Chojnacki, J., Pawlowska, E., Szczepanska, J., Chojnacki, C., & Blasiak, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810134 · Cited by 50
A cell atlas for migraine research
Holland, P. R., & Goadsby, P. J. (2022) · Nature · doi:10.1038/d41586-022-01479-4 · Cited by 2
Acceptance-Commitment Therapy for Women with Episodic Migraine: A Pilot Randomized Trial
Bernstein, C., Lazaridou, A., Paschali, M., Vilsmark, E. S., & Rist, P. M. (2024) · Journal of Integrative and Complementary Medicine · doi:10.1089/jicm.2023.0085 · Cited by 1
Metadata
- Authors
- Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 2021-06-23
- Volume
- 61
- Issue
- 7
- Pages
- 1021-1039
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W3173551259
- Cited by
- 766
- References
- 135
- FWCI
- 74.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.